Leadership
-
Getty Images
The clinical candidates pharma execs are tracking
Industry leaders at JPM this week revealed which up-and-coming assets they’re watching from other companies in oncology and neuroscience.
By Meagan Parrish • Jan. 16, 2026 -
Getty Images
Opinion // Year in PreviewPharmaVoice’s Crystal Ball: What’s next for AI and drug R&D
Industry execs foresee drug innovation and AI breakthroughs in 2026.
By Meagan Parrish • Jan. 9, 2026 -
Explore the Trendline➔
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Theo Wargo via Getty Images
Billionaire Sean Parker has already shaken up cancer R&D. Can his nonprofit fix the funding gap?
The entrepreneur’s cancer institute is striving to be the financial glue for an embattled research community while going beyond therapies and creating cures.
By Michael Gibney • Jan. 8, 2026 -
Alex Wong/ via Getty Images
The wellness industry is HHS’ new belle of the ball
Congressional leaders and health experts are sounding the alarm about potential conflicts of interest among the agency’s new leaders.
By Kelly Bilodeau • Jan. 8, 2026 -
Getty Images
C-suite priorities give a sneak peek into AI’s pharma future
While some are still leery of the technology, leaders see AI as a way to boost efficiency and cut costs.
By Kelly Bilodeau • Jan. 7, 2026 -
Getty Images
Opinion // Year in PreviewPharmaVoice’s Crystal Ball: Market and policy forces shaping the industry
How pharma leaders believe the regulatory and investment market landscape will change in 2026.
By Meagan Parrish • Jan. 6, 2026 -
Getty Images
Biopharma CEO optimism is wavering in the US
The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.
By Kelly Bilodeau • Dec. 22, 2025 -
Permission granted by Biogen
Q&ABiogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth
Guy Hadari discusses how his role has changed with the introduction of new technologies, and what that means for Biogen’s future.
By Michael Gibney • Dec. 19, 2025 -
Getty Images
5 CDER directors in one year? Turnover threatens ‘institutional memory’ at US health agencies.
Rapid movement among regulators’ top brass has contributed to an inconsistent strategic direction — but there’s hope in bureaucracy.
By Michael Gibney • Dec. 16, 2025 -
Permission granted by Intellus
Sponsored by Intellus WorldwideUnifying life sciences insights to accelerate enterprise value
Unified insights yield enhanced organizational strategic value, unlocking cross-functional innovation and reducing costs.
By Fabrice Dussol, AplusA Research, Head of US Commercial Strategy, Lynn Ricker, KnowVanta, Principal & Founder, and Diana Pohle, BioMarin Pharmaceuticals, Head of Business Insights & Analytics • Dec. 8, 2025 -
Permission granted by BeOne
Q&ABeOne brought Brukinsa to the blood cancer mountaintop. Can it hit those heights again?
The company’s chief medical officer discusses its trajectory with the blockbuster Brukinsa and its strong hematology pipeline.
By Michael Gibney • Dec. 4, 2025 -
Getty Images
A drugmaker charts a path through pharma’s ethical minefields
As the science behind pharma breakthroughs becomes more complex, bioethicists are helping companies navigate moral quandaries.
By Kelly Bilodeau • Dec. 1, 2025 -
Win McNamee via Getty Images
Pharma faces a critical ‘turning point’ in 2026, years in the making
While Trump’s manufacturing and pricing deals with pharma shape the industry’s future, COVID’s impact still ripples throughout the health landscape.
By Michael Gibney • Nov. 21, 2025 -
Getty Images
How do Big Pharma employees rate their CEOs?
There are many ways to steer the ship as the top exec of a large pharma company. Here are the ones employees approve of the most — as well as those who could polish their image a little more.
By Alexandra Pecci • Nov. 20, 2025 -
Permission granted by Alnylam
ProfileRNAi looked doomed to fail — until Alnylam’s science chief found a way
Kevin Fitzgerald, Alnylam Pharmaceuticals’ chief scientific officer, reveals the hard times that led to RNAi success, and what it takes to pave new roads in biotech.
By Michael Gibney • Nov. 13, 2025 -
Permission granted by Geron
Q&A // First 90 DaysAfter a lackluster first drug launch, a new CEO is finding Geron’s commercial footing
Harout Semerjian, whose pedigree includes launching the Novartis cancer blockbuster Gleevec, is aiming to boost awareness about Geron’s Rytelo to give it momentum.
By Alexandra Pecci • Nov. 12, 2025 -
Getty Images
Why Pfizer and Novo are duking it out over weight loss startup Metsera
A brutal bidding war between two industry giants over a clinical-stage drugmaker is a sign of the weight loss arena’s high stakes.
By Michael Gibney • Nov. 6, 2025 -
Tasos Katopodis via Getty Images
How Trump’s do-or-die agenda is impacting Big Pharma’s CEO chatter
Among tariffs, pricing policies and ongoing negotiations, pharma leaders can’t help but address their dealings with the Trump administration in third-quarter earnings reports.
By Michael Gibney • Oct. 30, 2025 -
Courtesy of Novo Nordisk
What comes next for Novo Nordisk?
After losing its leading position in obesity, changing its CEO and triggering a major company reorganization, the pressure is on Novo to pull off a major about-face.
By Kelly Bilodeau • Oct. 29, 2025 -
Getty Images
Novartis’ $12B Avidity deal shows a willingness to take big swings in neuroscience
A premium paid for RNA candidates reflects what the pharma giant has sought to do for the last few years: aim at revolutionary technology that fits into their own expertise.
By Michael Gibney • Oct. 28, 2025 -
Mike Coppola via Getty Images
J&J’s orthopedics selloff keeps all eyes on a thriving pharma portfolio
As another J&J department bites the dust, leadership is focused on what’s working in the pharma business, and there’s plenty to see.
By Michael Gibney • Oct. 16, 2025 -
Permission granted by Teva
Q&AOvercoming past mistakes, generics powerhouse Teva embraces an innovative ‘mindset change’
In the three years since a leadership change, Teva has evolved its R&D approach beyond a long history making copycat medicines.
By Michael Gibney • Oct. 7, 2025 -
Leon Neal via Getty Images
With Emma Walmsley exiting GSK, who will be pharma’s top women CEOs?
The only woman to head up a company in Big Pharma is stepping down from the role at the end of the year.
By Meagan Parrish • Oct. 3, 2025 -
Getty Images
Top pharma industry conferences in 2026
Where pharma leaders will converge, discuss and navigate the industry’s shifting landscape in 2026.
By Meagan Parrish • Updated Jan. 26, 2026 -
Getty Images
Why drugmakers may need to borrow from quantum theory to confront tariff and pricing threats
With so many unknowns surrounding regulatory and policy shifts, pharma companies might need to consider fundamental changes to how they operate, a Deloitte analyst said.
By Michael Gibney • Sept. 3, 2025
